Original Article

# Preeclampsia And Normotensive Pregnant Females Material Serum Endoglin Evalution Dr Vinay V Raman, Post Graduate Cum Tutor, Department Of Biochemistry, BMC&RI

**Dr. Vinay V Raman[1] , Dr. (Prof) Maruthi Prasad B V[2] , Dr. (Prof) Vishwanath B L[3]**

[1]Post Graduate cum Tutor, Department of Biochemistry, BMC&RI
[2]Department of Biochemistry, BMC&RI
[3]Head of Department, Department of Biochemistry, BMC&RI
**DOI:** 10.47750/pnr.2023.14.03.386

## Abstract

An unbalance of angiogenesis, including soluble endoglin, exists that causes preeclampsia. Preeclampsia patients had considerably higher serum soluble endoglin levels compared to women who were not experiencing any complications during their pregnancies.

Comparing the serum concentrations of soluble endoglin between pregnant women experiencing preeclampsia and those who had normal blood pressure. Forty pregnant women who were at least 20 weeks along were split evenly into two groups: those with preeclampsia and those without. Venipuncture was used to collect 5ml of blood into a test tube without the use of anticoagulant. Kits were used to perform a one-step sandwich enzyme immunoassay on plasma endoglin with monoclonal antibodies specific to human endoglin. The blood soluble endoglin level was significantly greater in the preeclampsia group (18.52 9.54 vs. 2.2 1.4, p= 0.000), and there was positive association between an elevated serum endoglin level and the probability of pre-eclampsia (r=0.523, P=0.016). The optimal sensitivity and specificity was found at the former was greater whereas the latter was lower than the threshold value of 6.26500 ng/ml.The diagnostic accuracy of serum soluble endoglin for preeclampsia is exceptional.

**Keywords-** Preeclampsia, Serum soluble endoglin.

## Introduction:

Preeclampsia is a disorder that is associated to pregnancy that is characterized by increased blood pressure and proteinuria. This condition is detected in 2%–8% of all pregnancies worldwide(1) following the twentieth week of pregnancyBecause of this, it is the primary cause of maternal illness and death, their unborn children. In wealthy nations, it is responsible for up to 16 percent of maternal mortality (2). Pregnancy-related hyperemesis gravidarum affects multiple body systems was during second as well as third trimester of pregnancy.increased blood pressure of at least 30 mm Hg on the systolic or 15 mm Hg on the diastolic side, or a pulse rate of at least 140 beats per minute, combined albuminuria equal to or greater to 300 mg/24 hours after the twentieth week of pregnancy are diagnostic criteria (3).

Despite the extensive research into potential causes and potential mitigation strategies, no foolproof preventative measures have been identified (4). An individual has preeclampsia if they have hypertension and one or more of the following symptoms:thrombocytopenia kidney damage (serum creatinine of 1.1 mg/dl or more, or to double excluding other causes of renal dysfunction, similar as serum creatinine), lung fluid accumulation (platelet count of 100,000/ml), and reduced lipid metabolism (intrahepatic

individuals that suffer to twice the usual level retention, or a newly developed infection are all indications that the patient should be hospitalized (5).

Even though there has been new study into the causes of preeclampsia, it is still a difficult disease to treat because the only proven method of both therapy and prevention is delivery of the baby in order to put an end to both the pregnancy and the disease (6). According to the current hypothesis of the pathogenesis of preeclampsia, decreased placenta circulation, which would be predominantly produced by aberrant trophoblastic infiltration, is followed subsequent intimidatory remodelling and maternal artery making sure the placental, and precedes and results in preeclamptic symptoms (7).

Preeclampsia is linked to a number of different things, including constitutional female features, antiangiogenic factors, and inflammatory activation. These elements include:

It has been postulated that inadequate placentation is a primary contributor to the pathophysiology of preeclampsia(8). It is believed that endothelial dysfunction is a main mechanism in preeclampsia pathogenesis Ischemia of such placental results in the release of liquids into the circulatory system. Chemicals such as these have been related to endothelial function including preeclampsia (9). Improved pregnancy outcomes may also be achieved through the use of soluble result measurement as a valid screening method among high-risk women before the onset of preeclampsia.

## Patients And Methods:

Forty pregnant women who had reached at least 20 weeks of gestation have been participated in Participants in the study have been assigned randomly to either the preeclamptic category or even the non-preeclamptic category.

## Type of Study:

A study of cases and controls.

## Location for study:

Maternity Hospital.

## Study period:

From October 2020 through June 2021, inclusive.

## Standards for admittance:

Women between the ages of 18 and 35 who are carrying only one baby, have gestational age exceed 20 weeks, while have a body mass index of less than 30.

## Exclusion criteria:

Women who have been diagnosed with a previous medical condition, such as conditions such as hypercoagulability, thrombophilia, diabetes, hypertension, cardiovascular disease, autoimmune illness, kidney disease, and liver disease are all linked to an increased risk of developing DVT. numerous pregnancies, or congenital fetal deformity.

## Research methodologies:

Following permission from the Medical School's Ethical Review Board, the study got underway. Everyone who participated gave their consent after receiving appropriate information. The confidentiality of the data was preserved.Blood was collected through drawing blood into the a test tube in the gynecology and obstetrics hospital's laboratory without the use of an anticoagulant, so that clotting could take place. Centrifugation at room temperature, 2000 RPM for 20 minutes, isolated the serum. Before the clotting process was finished, we did not do a centrifuge. After that, blood samples were sent to the They were stored at -20 degrees Celsius in the laboratories of Microbiology as well as Immunology of the University of Medicine's Faculty of Medicine. The soluble endoglin levels in the human serum sample were measured using this kit. Monoclonal antibodies specific for human endoglin were used in

an each sandwich enzyme - linked immunosorbent assay to determine plasma endoglin levels. The sets were acquired independently.
The correlation amongst serum soluble endoglin levels and preeclampsia wasthe main thrust of our investigation.
There was no significant difference in the bloodstream endoglin concentrations for patients suffering preeclampsia compared to those of cognitively intact pregnant women, which was a secondary outcome we examined.

## An Examination of Statistics:

SPSS version 20 was used for the tabulation as well as statistical analysis of the data (SPSS Inc.,Chicago, IL). We utilized the Independence Aside from other possible reasons of renal failure (e.g., elevated serum creatinine), lungs fluid qualitative features test present across the different groups. The qualitative information was presented in the form of frequancies (n) and percentages (%). To determine the degree of correlation between quantitative variables, the Pearson correlation coefficient was utilized. When the p-value was less than 0.05, statistical significance was assumed.

## Results:

None of the demographic characteristics were significantly different between the study groups just at time they were recruited. Statistics showed that measures such as urinary albumin, ALT, AST, hematocrit levels, creatine, even uric acid differed significantly between the groups.
In contrast to the normative sample, preeclampsia group had a much greater endoglin level. This difference was statistically found to be highly significant by utilizing the Statistics known as the Mann-Whitney test. The successful outcome of keeping the gestation underneath controlled indicated (2.2 1.4). Research participants discovered the following: (18.52 9.54) In addition, a greater blood soluble endoglin level was linked to a higher risk of preeclampsia ($r = 0.523$, $P = 0.016$).

## Discussion:

Compared to those without preeclampsia, people who had mild, moderate, or severe preeclampsia had sEng concentrations that were 3, 5, and 10 times higher, respectively. particularly serious HELLP disorder than that in gestation time of life premature counterparts as compared to those of healthy pregnant women (8). Multiple prior studies were confirmed by this one.
According to Levine and his colleagues, an increase in the amount of soluble endoglin that is circulating in the blood signals the beginningcause by preeclampsia As part of a larger nested case-control research called Calcium for Preeclampsia Prevention, analysis was carried out on healthy women who had not previously given birth.
Seventy-two women with a 37-week preterm preeclampsia diagnosis and another four hundred and Eighty female participants were chosen at random for the study. A total of 120 women experienced term-onset preeclampsia At 37 weeks, 120 women with gestational hypertension, 120 women with normal blood pressure gave birth to babies small by their gestational, while 120 women with normal blood pressure gave birth to babies that were average in size for their gestational age of normal size but had babies that were not small for their age at birth as controls (9).
According to the research conducted by Robinson and Johnson, the levels of soluble endoglin that are present in the maternal serum during the second trimester are higher in individuals who have a greater risk of developing severe preeclampsia. Single moment serum samples were evaluated by enzyme-linked immunosorbent assay in 48 smoke free women whose developed severe preeclampsia and 56 nonsmoking women who had healthy pregnancies. In comparison to The sEng levels of pregnant women who did develop preeclampsia were substantially higher than the rates seen in pregnant women who do not develop preeclampsia (10).
According to Gu and his coworkers, normal trophoblast cells do not create as much sEng as do PE trophoblast cells (TCs). Conditions with less available oxygen encourage synthesis of sEng by PE TCs. Placentas from PE patients had a higher concentration of glycosylated sEng. TCs were grown from normal and PE placentas in conventional and decreased oxygen conditions, respectively (11)

Ali and Mohammed found that the endoglin levels of preeclamptic women were significantly greater than those of normal moms. In this study, 50 pregnant women that had already entered labor participated was conducted; of these women, 25 had normal pregnancies and the remaining 25 had preeclampsia. Following birth, maternal serum was collected from each patient and then forwarded to a laboratory for endoglin analysis (12).

According to Rana and her colleagues,Women who developed preeclampsia had plasma sEng levels (30.212.7, 55.7) as well as gestational HTN (6.24.5, 14.0) that were substantially greater than those of non-hypertensive females (4.83, 5.13, 7.11; p0.0001 and p=0.04, respectively). All presenters had their sEng skills assessed before the show Among the women in this research who presented for evaluation of preeclampsia between weeks 34 and 36 of a singleton pregnancy, between July 2009 and October 2010, and this study included their data. Those persons who had unfavorable outcomes had significantly greater levels of sEng (ng/ml) compared to those individuals who did not have unfavorable outcomes (32.3 18.1, 55.8 vs 4.83.2, 8.6, p0.0001) (13) .

The results of Rana's study and those of her colleagues were similar, although they selected a different number as their threshold for significance. They used a cut-off for sEng of 12 ng/ml, and discovered that 107 (62.9%) of the participants were at or below the cut-off, while 63 (37.1%) were over. The cut-off was used to determine who was at or below the cut-off.

With a sensitivities of 80.4%, selectivity of 88.6%, PPV of 77.6%, NPV of 90.26%, adjusted hazard ratio This cutoff showed very good diagnostic accuracy for bad outcomes (LR 7.1, LR 0.2).(13).

Using maternal factors and sEng, prenatal screening for PE can be performed between weeks 30 and 33 of pregnancy, according to Lai and his colleagues' findings, locate the vast majority of PE-affected pregnancies. The median sEng Mom for the PE group was 1.39 (IQR 0.94-2.18) compared to 0.95 (IQR 0.77-1.19) for the control group at 30 and 33 weeks. This difference was not statistically significant at 11-13 weeks (15). The IQR for the PE group was 0.94–2.18, while the IQR for the controls was 0.77–1.19.

According to Lai and his colleagues, The ROC curves andScreen predicated upon maternal variables and third-trimester sEng had a false-positive incidence of 7.5% and 10% for intermediate and late-stage PE, respectively. Diagnosis accuracy was 64.3% for transitional as well as 50.0% for late-PE when screening for PE using a mixture including maternal features with third-trimester sEng, with such a rate of false positives of 10% with each (15). In 50% of the instances, a late-PE form was identified.(16).

Using insoluble endoglin as a model, Gaber and coworkers investigated the protein's potential as a novel marker for the early detection of cancer. detection of preeclampsia in pregnant women. They observed that the ROC curve demonstrated that sEng was able to differentiate preeclamptic pregnancies from normal pregnancies. On the AUC scale,A 0.962 was the final tally for that. The sensitivity was as high as 95% at a cutoff of 7 ng/ml (17) found to be 94.4 percent, the specificity was found to be 87.5 percent, and the accuracy was found to be 89.5 percent.

Final results from Maximum sensitivity and specificity for sEng was found at a blood level of 21.1 ng/mL, as shown by the receiver operating characteristic curve for discriminating preeclamptic women from those with normal pregnancies. An AUC of 0.924(18) was calculated by contrasting the 90th, 83rd, and 84th percentiles.

## Conclusion

In the Calcium during Preeclampsia Management study, researchers discovered that Concentrations of sEng reported three-five over ten-fold higher in individuals with severe, HELLP, and moderate cases of the syndrome, respectively higher than those of gestational age-matched preterm controls. To identify who'd been below or above the cut-off for sEng, a value of 12 ng/ml was employed, exhibiting high diagnostic performance for adverse outcomes. Most cases of PE can be detected with screening at 30–33 weeks of pregnancy utilizing maternal features and sEng. By comparing PPV and NPV,To achieve the best balance of sensitivity and specificity, Lee's group determined that 21.1 ng/mL was the optimal serum concentration.

When it comes to diagnosing preeclampsia, serum soluble endoglin seems to have a remarkable degree of success.

## REFERENCES:


1. Jeyabalan, A. (2013). Epidemiology of preeclampsia: impact of obesity. Nutrition reviews, 71(suppl_1), S18-S25.

**2.** Khan, K. S., Wojdyla, D., Say, L., Gülmezoglu, A. M., & Van Look, P. F. (2006). WHO analysis of causes of maternal death: a systematic review. The lancet, 367(9516), 1066-1074.

**3.** Wagner, S. J., Barac, S., & Garovic, V. D. (2007). Hypertensive pregnancy disorders: current concepts. The journal of clinical hypertension, 9(7), 560-566.

**4.** de Jonghe, B., Lacherade, J. C., Sharshar, T., & Outin, H. (2009). Intensive care unitacquired weakness: risk factors and prevention. Critical care medicine, 37(10), S309-S315.

**5.** Mayer-Pickel, K., Stern, C., Eberhard, K., Lang, U., & Cervar-Zivkovic, M. (2019). Changes of platelet count throughout pregnancy in women with antiphospholipid syndrome. Journal of reproductive immunology, 136, 102612.

**6.** Wallace, K., Harris, S., Addison, A., & Bean, C. (2018). HELLP syndrome: pathophysiology and current therapies. Current pharmaceutical biotechnology, 19(10), 816-826.

**7.** Gilbert, J. S., Ryan, M. J., LaMarca, B. B., Sedeek, M., Murphy, S. R., & Granger, J. P. (2008). Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. American Journal of Physiology-Heart and Circulatory Physiology, 294(2), H541-H550.

**8.** Venkatesha, S., Toporsian, M., Lam, C., Hanai, J. I., Mammoto, T., Kim, Y. M., ... & Karumanchi, S. A. (2006). Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature medicine, 12(6), 642- 649.

**9.** Levine, R. J., Lam, C., Qian, C., Yu, K. F., Maynard, S. E., Sachs, B. P., ... & Karumanchi, S. A. (2006). Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New England Journal of Medicine, 355(10), 992-1005.

**10.** Robinson, C. J., & Johnson, D. D. (2007). Soluble endoglin as a second-trimester marker for preeclampsia. American journal of obstetrics and gynecology, 197(2), 174- e1.

**11.** Gu, Y., Lewis, D. F., & Wang, Y. (2008). Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. The Journal of Clinical Endocrinology & Metabolism, 93(1), 260- 266.

**12.** Ali, S. A., & Mohammed, A. I. (2010). Comparative Study Between Maternal Serum Level Of Soluble Endoglin In The Normal Pregnancy And Those Of The Preeclampsia. Aamj, 8(3).

**13.** Rana, S., Cerdeira, A. S., Wenger, J., Salahuddin, S., Lim, K. H., Ralston, S. J., ... & Karumanchi, S. A. (2012). Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PloS one, 7(10), e48259.

**14.** Elhawary, T. M., El-Bendary, A. S., & Demerdash, H. (2012). Maternal serum endoglin as an early marker of preeclampsia in high-risk patients. International journal of women's health, 4, 521.

**15.** Lai, J., Syngelaki, A., Poon, L. C., Nucci, M., & Nicolaides, K. H. (2013). Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia. Fetal diagnosis and therapy, 33(3), 149-155.

**16.** Abd El-Dayem, T. M., Elagwany, A. S., Khamis, M. Y., Kamha, E. S., & Hassan, A. M. M. (2016). Correlation of serum soluble endoglin to the severity of pre-eclampsia and its effect on the pregnancy outcome. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 5(5), 1594.

**17.** Gaber, K., Hamdy, E., & Hanafy, A. (2010). Soluble endoglin as a new marker for prediction of pre-eclampsia in early pregnancy. Middle East Fertility Society Journal, 15(1), 42-46.

**18.** Lee, H. B., Kil, K. C., Nam, S. Y., Shin, J. E., Cheon, J. Y., & Lee, Y. (2011). Clinical usefulness of soluble fms-like tyrosine kinase 1, soluble endoglin and placental growth factor in Korean women with preeclampsia. Korean Journal of Obstetrics & Gynecology, 54(5), 229-235.